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The purpose of this study was to determine the charges for
radiofrequency catheter modification of the atrioventricutar (AV)
node in 15 patients with symptomatic AV node reentrant tachy-
cardia despite pharmacologic therapy and to compare these
charges with the estimated charges for health care utilization by
the same patients before the catheter procedure was performed .
There were seven men and eight women with a mean age of 50
17 years. The mean duration and frequency of symptoms were 16
t 9 years and 4.5 t 6 episodes/month, respectively
. Fourteen of
the 15 patients required only one procedure for diagnosis and cure
of AV node reentrant tachycardia and I patient required two
sessions . All patients underwent electrophysiologic study before
discharge from the hospital to confirm the short-term efficacy of
the procedure.
The mean duration of the hospital stay was 3 ± 1 .5 days and
the mean total eharge/patient expvssed in 1991 dollars was
The most common type of paroxysmal supraventricular
tachycardia is atrioventricular (AV) node reentrant tachy-
cardia (1-3). Although it may be effectively suppressed by
empiric antiarrhythmic drug therapy, symptomatic episodes
may recur in some patients despite pharmacologic therapy .
Furthermore, because paroxysmal supraventricular tachy-
cardia rarely if ever results in death or life-threatening
complications, some patients with this arrhythmia may con-
tinue to experience symptomatic episodes over a period of
many years .
Catheter modification of the AV node with the use of
radiofrequency energy has been demonstrated (4,5) to be
effective in eliminating paroxysmal supraventricular tachy-
cardia in the majority of patients who have AV node
reentrant tachycardia. Although the clinical benefit to pa-
tients of eliminating symptomatic paroxysmal supraventric-
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$15,893 t $3,338 for catheter modification . These total charges
consr1ed of hospital charges of $8,105 ± $2,466 and physician
charges of $7,788 A $971. All patients had a successful outcome
and required no additional antiarrhythmic therapy . The esti-
mated cost of health rare utilization for these 15 patients before
cure of AV node reentrant tachycardia was $7,tSVpatient per
year . These estimated costs included charges incurred for ener-
gency room visits, office visits, hospitalizations and antiarrhyth-
mic drug therapy.
In conclusion, the results of this study indicate that the annual
health care costs incurred by patients who have symptomatic,
dog-refractory paroxysmal sapraventricutar tachycardia caused
by AV node reentry are substantial . Radiofrequency catheter
modification of the AV node not only is of clinical benefit, but also
results in a dramatic long-term reduction in medical expenses .
(J .4m Call Cardinl 1992;I9:1583-7)
ular tachycardia are clear, the economic impact of curing
this form of tachycardia by radiofrequency modification of
the AV node in patients with drug-refractory AV node
reentrant tachycardia has not been previously analyzed
.
Therefore, the purpose of this study was to determine the
cost of radiofrequency modification of the AV node in a
group of patients with a long history of symptomatic parox-
ysmal supraventricufar tachycardia despite pharmacologic
therapy and to compare this cost with the medical expenses
incurred before the procedure as a result of the tachycardia .
Methods
Study design . This was a retrospective study of 15 pa-
tients who underwent successful radiofrequency catheter
modification of the AV node for treatment of AV node
reentrant tachycardia at the University of Michigan Medical
Center between January and July 1990 . Radiofrequency
catheter ablation was performed under a protocol approved
by the Human Research Committee at the University of
Michigan after informed written consent was obtained from
all patients . Patients were selected for analysis
if
they had
had a successful outcome of catheter modification of the AV
0135-1057921 55 .00
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node after unsuccessful pharmaeologic therapy and if they
were available for questioning by telephone . Hospital billing
records were reviewed to determine the hospital and physi-
cian charges related to the catheter modification procedure .
Records were reviewed and all patients were contacted by
telephone to determine the duration and frequency of symp-
toms, number and type of prior antiarrhythmic medications,
symptoms related to the tachycardia, presence of structural
heart disease, prior use of health care facilities (including
emergency room visits, office visits and hospital admissions)
and the number of days missed from work as a result of the
tachycardia.
Patient characteristics. There were seven men and eight
women with a mean age (±SD) of 50 ± 17 years. Thirteen
patients had no structural heart disease and two had coro-
nary artery disease. The mean duration and frequency of
symptoms were 16 ± 9 years •:md 4 .5 ± 6 episodes/month,
respectively. The patients had been unsuccessfully treated
with a mean of 2 .4 ± 1 .4 antiarrhythmic medications .
Digoxin had been used in 7 patients, verapamil in 10, a
beta-adrenergic blocking agent in 8, quinidine in 7 and
flecainide in 2 . Each patient continued to have symptomatic
tachycardia despite drug therapy and 9 of 15 patients expe-
rienced medication side effects . During the tachycardia, 14
patients had rapid palpitation, 10 had light-headedness, 8 had
chest pain, 8 had shortness of breath and 3 had syncopal
episodes.
Catheter ablation procedure . All patients underwent the
initial electrophysiologic procedure with the intent of diag-
nosis and cure during the same session (4) . The technique
utilized in these 15 patients, ablation of the retrograde fast
pathway of the AV node reentrant tachycardia circuit, has
previously been described (4,5). After the ablation proce-
dure, patients underwent continuous telemetric electrocar-
rliographic (ECG) monitoring in the hospital and underwent
electrophysiologic study 2 days after the procedure, before
hospital discharge, to confirm the short-term efficacy of the
procedure . If AV node reentrant tachycardia was inducible,
AV node modification was attempted again and another
electrophysiologic study was performed 24 to 48 h later . A
daily 12-lead ECO was obtained and creatine kinase and its
MB fraction were measured every 8 h for 24 h after the
procedure .
Catheter modification charg.-e. Hospital billing records
were reviewed to determine the hospital a,td professional
charges during the hospital admission in which the electro-
physiologic procedure was performed . All charges that were
related to management of the patient's AV node reentrant
tachycardia during this hospital stay were included . These
charges included all ECG studies, blood tests, chest X-ray
films, echocardiograms, medications and electrophysiologic
studies . Charges unrelated to management of the patient's
tachycardia were excluded .
Prior medical expenses. Charges for office visits, emer-
gency room visits and hospital admissions were based on
billing fees at the University of Michigan and were adjusted
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Table 1 . Annual Retail Cost of Various Antiarrhythmic Medications
bid = twice a day : qd = once a day; qid = four times a day : lid = three
times a day.
to 1991 dollar values . It was assumed that office visits were
of intermediate length and did not include an ECG . Emer-
gency room visits were assumed to be 1 .5 to 2 h in duration,
with one 12-lead ECG and 5 mg of intravenous verapamil for
termination of the tachycardia. The typical hospital stay was
estimated to have a duration of 2 days and to include
continuous telemetric ECG monitoring, a 12-lead ECG,
basic laboratory work and 5 mg of intravenous verapamil .
The estimated charges for office visits, emergency room
visits and hospital admissions were $70, $821 and $2,219,
respectively .
Total estimated charges for emergency room and office
visits/patient per year were based on the mean number of
office and emergency room visits for the group of 15 patients
during the year before cure of the AV node reentrant
tachycardia . The estimated charge for hospitalizations was
calculated by using the mean number of hospitalizations/
patient per year for the total duration of tachycardia symp-
toms . Medication charges were determined from the outpa-
tient pharmacy at the University of Michigan Hospitals and
were based on a 1-month refill schedule (Table I) . The
antiarrhythmic medications and dosages chosen for cost
analysis were those that were typically used by the patients
and are available at the University of Michigan outpatient
pharmacy. The estimated charges/patient per year for med-
ications were calculated by using a weighted average of the
cost of each antiarrhythmic drug used .
Results
The cumulative annual expenses incurred by patients
with paroxysmal supraventricular tachycardia due to AV
node reentry and the cumulative charges associated with
various types of therapy are shown in Figure I .
AV node modification. The age of the patients, number of
electrophysiologic studies performed, days of hospital stay,
hospital charges, physician charges and total charges are
listed in Table 2. The mean total charge for cur.
-r
AV node
reentrant tachycardia, $15,893 ± $3,338, comprised hospital
charges of $8,105 ± $2,466 and physician charges of $7,788
± $971 . The majority of hospital charges consisted of the
electrophysiologic laboratory fee and the daily room charge
for a monitored bed . Physician charges consisted primarily
of professional fees for the electrophysiologic studies . Of the
15 patients, only I required two electrophysiologic, proce-
Dose (mg) Cost (5)
Digoxin ILanoxial 0 .25 qd
106
Arenolol(Tenorminl
50 lid
340
Quinidine(Duraquin) 486 lid 551
Flecainide (Tambocor) 100 bid 710
verapamil (Calan) 120 qid s47
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Figure 1 . Cumulative charges for medical
care incurred ny patients with atrioven-
tricular (AV) node reentrant tachycardia
compared with the charges resulting from
catheter modification of the AV node and
surgical therapy for AV node reentrant
tachycardia . The cumulative charges in-
curred by long-term pharmacologic ther-
apy ; nclude the cost of an annual office
visit and electrocardiogram. The medical
expenses for the patients in this study
represent the mean charges incurred by 15
patients for management of paroxysmal
supraventricular tachycardia before ra .
diofrequency modification of the AV
node . Also shown for comparison are the
cumulative expenses incurred by a hypo-
thetical patient who requires one emer-
gency room (ER) visit each year for termi-
nation of AV node reentrant tachycardia .
All charges are expressed in 1991 dollar ;,
dures for cure of AV node reentrant tachycardia and this
second procedure sigeificantly increased the length of this
patient's hospital stay to 7 days and the total charges for the
procedure to $26,378 . The n,Yan duration of the hospital stay
for all patients was 3 ± 1 .5 days (:
ange 2 to 7).
Follow-up. Patients were questioned at a mean of 17 x 2
months after the catheter prccdAcc . No patient had had a
recurrence of symptomatic tachycardia or required antiar-
rhythmic drug therapy, office visits, emergency room visits
or hospital admission for treatment of paroxysmal supraven-
tricular tachycardia. In the year before catheter modifica-
tion, this group of patients had missed a mean of 13 - 26
days of work (range 0 to 100) because of episodes of
tachycardia. After the catheter procedure, no patient missed
any days of work because of tachycardia .
Previous medical expenses . The number of emergency
room visits, hospital visits, hospital admissions and their
associated costs are described in Table 3 . The estimated
total cost for medical therapy was $7,651 2 $8,496/patient
per year and consisted primarily of emergency room charges
for termination of AV node reentrant tachycardia. Six pa-
tients required >10 emergency room visits for control of the
tachycardia in the year before the radiofrequency catheter
modification procedure
. In the group as a whole, hospital
admissions were infrequent: 10 of the 15 patients had had
one or more hospital admissions for management of AV
Table 2. Hospital and Professional Charges for
IS patients Who Underwent Radiofrcquency
Modification of the Atrioventricular Node
EP = electrophysiologic : F = female: H = male : Pt = patient .
1
585
Pt No .
Age Iyr)l
Gender
No . of EP
Studies
Hospital
Days
Hospital
charges (s)
Physician
Charges ($)
Total
Charges IS)
I 541M
7,156 7.337 14.693
2 70IM 3 8,136
7,396 15,532
3 68IF 3 7 15,276 11,102 26,378
4 521F 6,769
7,412 14,181
5 6NM 9 .375
7,466 16,791
6 59ZM 7,631 8,025
15,656
7 3NF
6,982 8,015 14,997
8 38/M
8 .347 7,348 15.695
9 IS/F
6 .925 7,289 14,214
10 42/F
6,834 7,289 14,123
I I 28/F 2 4 .508
7
.385
11,893
12 71/M 2 3 7 .722 7,348
15,068
13 701F
7 .779 7 .783 15 .562
14
311M 6.691 7 .337 14,928
15 5610 11,287 8,294 19,581
:dean 50 8,105 7 .788 15 .893
--SD 17 0.03 15 2,466
971 5,33e
1 586
KALBPLEISCH ET AL .
	
]ACC Vol . 19, No. 7
COST OF THERAPY FOR AV NODE REENTRANT TACHYCARDIA
June 1992 :1510-7
Table 3.
Health Care Utilization and Charges in 15 Patients
in the Year Before Radiofrequency Modification of the
Atriovcnldcu
:ar Node
No.
Estimated Annual
Charges/Patient ($1
Emergency an. visits 7,5 ± 10
6,157 ± 8,374
Dice visits
6 .5 x 50 455
.
346
Hospital admissions per year for 0 .24 : 0.34 533 5 762
the total duration of symptoms
Medication costs
506
Total charges
Values are e,,pressod as mean values : SD. All charges are expressed in
1991 dollars.
node reentrant tachycardia at some time in the past . The two
patients with underlying coronary artery disease had had the
greatest number of hospital admissions
related to episodes of
tachycardia: 15 admissions at an estimated cost of $33,285 in
one and 10 admissions at an estimated cost of $27,190 in the
other.
Discussion
The main finding of this study is that symptomatic,
drug-refractory AV node reentrant tachycardia is an expen-
sive disorder to manage and that radiofrequency catheter
modification of the AV node is a cost-effective form of
therapy. Although the short-term cost of the procedure is
high relative to the cost of antiarrhythmic medications, over
the long-term the procedure results in significant cost sav-
ings in patients who continue to have episodes of paroxys-
mal supraventrieular tachycardia that do not terminate spon-
taneously
.
Comparison with surgical therapy . Cryosurgery or surgi-
cal dissection in the vicinity of the AV node can eliminate
AV node reentrant tachycardia (6,7). However, the catheter
approach can cure AV node reentrant tachycardia at a cost
that is less than one third that of the surgical approach . At
the University of Michigan, the total charges for surgical
therapy of supraucotricular tachycardia due
r,
the Wolff-
Parkinson-White syndrome in uncomplicated cases adjusted
to 1991 dollar values were $53,174 ± $4,292 and consisted of
hospital charges of $37,506 *_ $4 .076 and professional
charges of $15,668 ± $1,501
(8) . From the standpoint of
hospital charges and professional fees. the surgical treatment
of AV node reentrant tachycardia raouid be expected to be
similar to that of the Wolff Parkinson-White syndrome .
Patients who underwent cryosurgery for AV node reentrant
tachycardia were not used in this analysis because the few
patients who underwent this procedure at our institution also
underwent other surgical procedures . Nevertheless, it is
clear that the catheter modification approach offers a signif-
icant cost advantage over the anticipated cost of surgical
therapy for AV node reentrant tachycardia.
Comparison with other therapies . Antitachycardia pacing
also has been used to treat drug-resistant supraventricular
7.651 0 8.496
tachycardia. A recent study by Li et al
. (9) demonstrated
that the use of antitachycardia pacing for paroxysmal su-
praventricular tachycardia reduced the monthly medical
charges from $505 ± $833 before pacemaker implantation to
$105 ± $1 i7 after implantation, equivalent to a reduction in
the mean annual cost from $6,060 to $1,260. In that study, in
which charges were expressed in 1987 dollars, the charge for
pacemaker implantation was $19,063 ± $8,362, not including
pacemaker follow-up charges . Therefore, in addition to
obviating the need for pacemaker implantation and follow-
up, radiofrequency modification of the AV node is less
expensive than antitachycardia pacing.
Complete ablation of the AV node and implantation of a
permanent pacemaker is another possible form of therapy
for AV node reentrant tachycardia . In a study by Rosengvist
ct al
.
(10), 26% of patients who underwent catheter ablation
of the AV junction with direct current shocks had AV node
reentrant tachycardia. After the ablation procedure, hospital
admissions decreased from a mean of 2 .4 to 0
.31year . The
cost of this procedure was not specified, but would include
the cost of the ablation procedure plus the cost of a dual-
chamber pacemaker, which in itself carries an initial implan-
tation cost of approximately $16,000 at our institution .
Therefore, catheter ablation of the AV junction is less
cost-effective than radiofrequency catheter modification of
the AV node in patients with AV node rccatrant tachycardia .
Aside from economic considerations, catheter ablation of
the AV junction, because it results in pacemaker depen-
dency, should have only a very limited role in the manage-
ment of patients with AV node reentrant tachycardia .
Comparison with effective pharmacologie therapy . In pa-
tients who have paroxysmal supraventricular tachycardia
refractory to medical treatment and require frequent emer-
gency room visits or hospitalizations, the economic advan-
tage of definitive therapy is clear . However, in patients
whose tachycardia is effectively controlled by medications,
the cost-effectiveness of catheter modification is less clear .
Table I lists the annual cost of several antiarrhythmic
medications used to treat AV node reentrant tachycardia . In
young patients who require the more expensive medications,
such as verapamil, flecainide or quinidine gluconate, the
catheter procedure may be justified from a cost standpoint
because the cumulative cost of these medications would
equal the cost of the catheter modification procedure within
approximately 20 to 30 years . In addition, if the patient has
a yearly office visit and ECG, the incremental cost would be
approximately $1701year, making catheter modification an
even more attractive alternative from a cost standpoint,
Limitations
. The major limitation of this study is an
inherent selection bias . All patients in this study had not
responded to medical therapy ; most were severely sympto-
matic and required multiple emergency room visits and
hospital admissions. Therefore, the cost of medical care
incurred by these patients may not be representative of those
incurred by the typical patient who continues to experience
episodes of paroxysmal supraventricular tachycardia despite
JACC Val . 19, No. 7
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pharmacologic therapy
. For example, if a patient required
only one emergency room visit each year plus basic periodic
follow-up and medications, the estimated annual medical
expenses would be $1,501, only 20% of the annual medical
expenses of the patients in this study . However, even in this
type of patient, the health care costs would exceed $15,000
in 10 years, making the catheter modification procedure
cost-effective over the long-term .
In the two largest series of patients treated with the
catheter modification procedure (4,5), the combined overall
long-tern success rate for treating typical AV node reentrant
tachycardia was 89% . Thus, in up to 11% of patients, the
catheter modification charges may be incurred without cur-
ing the AV node reentrant tachycardia.
Although no patient in this study had a complication
during the hospital stay, radiofraquency modification of the
AV node may result in complete AV block . When the two
largest reported series (4,5) were considered together, this
complication occurred in 4 (4 .7%) of 85 patients . Implanta-
tion of a permanent pacemaker carries an initial implantation
charge of up to $16,000 . This could approximately double the
overall charges in up to 5% of patient .; undergoing :diefre-
quency modification of the AV node with the technique used
in this study .
The cost analysis in this study applies to patients who
have paroxysmal supeaventricular tachycardia caused by
AV node reentrant tachycardia
. Although ECG findings may
suggest that AV node reentry is present, electrophysiologic
study is usually required to define the mechanism of parox-
ysmal supraventricular tachycardia . Therefore, Inless the
patient has undergone electrophysiologic study- it may be
unclear whether the cost analysis presented here is relevant .
It should be noted that AV node reentry accounts for
approximately 60% of paroxysmal supraventricular tachy-
cardias and that orthodromic AV reciprocating tachycardia
using a concealed accessory pathway accounts for approxi-
mately 30% of paroxysmal supraventricular tachycardias
(1-3)
. A prior study (9) demonstrated that the charges
associated with radiofrequency catheter ablation of acces-
sory pathways is approximately 515,000, very similar to the
charges associated with radiotrequency modification of the
AV node . Therefore, although the clinician may often not
know the exact mechanism of paroxysmal supraventricular
tachycardia, the cost analysis presented in this study will
apply to the vast majority of patients with this disorder.
Conclusions . In patients who respond well to pharmacy
logic therapy, the cumulative charges for medications and an
annual office visit and ECG would exceed the charges for
radiofrequency modification of the AV node after approxi-
mately 15 to 60 years, depending on the particular medica-
tion used
. In younger patients who may require treatment for
1587
>20 to 30 years, radiofrequency modification of the AV node
would be less expensive over the long-term than would
therapy with medications such as atenotol, quinidine glu-
conate, flecainide and verapamil . Therefore, in many pa-
tients in whom AV node reentrant tachycardia is controlled
but •.oho may prefer definitive therapy as en arernatne to
life-long pharmacologic therapy, radiofrequency modifica-
ticn of the AV node will also provide a long-term economic
advantage .
In patients who do not respond well to pharmacologic
therapy and who experience episodes of" node reentrant
tachycardia that require termination with intravenous med-
ication, the economic advantage of definitive therapy is more
dramatic. In patients who must visit an emergency room
once a year, the cumulative charges will exceed the charges
associated with radiofrequency modification after approxi-
mately IO years. However, in patients such as those in this
study, who require several emergency room visits each year,
the charges related to mdiofrequency modification of the AV
node may be exceeded after only 2 years . In such patients,
definitive catheter therapy provides not only important clin-
ical benefits, but also results in major long-term cost savings.
We are
grateful
to Marion Maguire for expert preparation ofthe manuscript .
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